Navigating the Evolving Oncology Landscape
The Oncology Business Unit was created in February 2016. A dedicated team of oncology industry experts from backgrounds in policy, research, and cancer institutions collaborated on the identification of key trends within the expanding marketplace. "The Access Group is committed to the success of the Oncology Business Unit and our clients navigating the evolving healthcare landscape," said Eric Bishea, CEO. "This commitment means continual elevation of its value with investment in key resources such as talent and strategic partnerships."
The Oncology Business Unit applies proprietary models and tools to convert large amounts of practice and adoption pattern data into actionable insights. By partnering with Government, Policy, Systems, another division of the Access Group, the Oncology Business Unit uncovered implications for formulary coverage and access to care for oncology treatment manufacturers.
Charting a Course for the Biopharmaceutical Industry
With this new information and research, the Oncology Business Unit is primed to share its findings with the industry. On an ongoing basis, the group authors original publications of their insights and applies them in recommendations and guidance to manufacturers. Alternate payment models, patient financial toxicity and burden, oncology pathways, and access-centered journey simulations for any given tumor type are just a few areas manufacturers can better navigate as a result of the insights provided by the Oncology Business Unit.
Now, less than a year since its debut, the Oncology Business Unit has expanded its oncology partnerships and engagements by nearly 10-fold, as measured by the number of tumor types, indications, product launches, and treatment modalities.
"Beyond research and development, the rate of oncology commercialization for underserved and challenging cancers is growing exponentially to soon break the $100 billion ceiling," said Gruenglas. "The Oncology Business Unit division has yielded insights and strategies that are being implemented to facilitate and expedite access to care for a current range of solid tumors. We look forward to developing future applications across other oncology therapy platforms."
About the Access Group
The Access Group is a leading independent strategic health care communications network composed of 5 distinct entities: Bioeclipse, Catalyst, FronTier Managed Markets, MedAccess, and Promidian. Also included are 4 specialized service groups: S3 — Strategic Selling Solutions; Government, Policy, Systems; the Oncology Business Unit, and StrataMed. The company employs more than 130 health care marketing specialists, consultants, and senior leaders with experience in management consulting, brand promotion, marketing communications, managed markets, medical education, and training.
The Access Group is headquartered in Berkeley Heights, New Jersey, with offices in New York City, Chicago, Boston, San Diego, Los Angeles, and San Francisco. To learn more about the Access Group, please visit www.theaccessgp.com or contact Eric Bishea, CEO, at (908) 508-6700.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-access-group-recognized-for-oncology-leadership-agencys-oncology-business-unit-receives-praise-from-prominent-industry-publication-300381333.html
SOURCE The Access Group